Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

117
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
117
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

665
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
665
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

6.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

80
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Lipid Catabolism01:25

Lipid Catabolism

1.4K
Triglycerides serve as crucial long-term energy storage molecules in microorganisms, providing a dense source of metabolic energy. Their breakdown is mediated by lipases, which hydrolyze triglycerides into glycerol and free fatty acids. Each of these components follows distinct metabolic pathways, ultimately contributing to ATP synthesis and cellular energy homeostasis.Glycerol MetabolismGlycerol, released from triglyceride hydrolysis, is phosphorylated by glycerol kinase to form...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small, dense LDL-C as a predictor of cardiovascular risk and benefit of alirocumab in patients with recent acute coronary syndrome receiving optimized statin treatment.

American journal of preventive cardiology·2026
Same author

Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome.

European heart journal·2026
Same author

LDL Cholesterol: How Low to Go?

Journal of the American College of Cardiology·2026
Same author

Adaptive AI for Cardiovascular Event Adjudication: Cardiovascular Event Adjudication Across Different Definitions in the ODYSSEY OUTCOMES and EUCLID Trials.

Circulation·2026
Same author

Inclisiran in Patients with CKD: Post Hoc Pooled Analysis of Three Phase 3 Trials.

Journal of the American Society of Nephrology : JASN·2026
Same author

Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.

Circulation·2025
Same journal

Retargeted adenoviruses for local IgA and CD47 blocker production as a novel cancer therapy.

EMBO molecular medicine·2026
Same journal

CD4-directed nanoblades enable selective genome editing in CD4<sup>+</sup> cells and HIV suppression in vitro and in vivo.

EMBO molecular medicine·2026
Same journal

Foxs1-mediated transformation of CD34<sup>+</sup> fibroblast to myCAFs promotes tumor growth.

EMBO molecular medicine·2026
Same journal

Patient-derived resources for decoding and targeting brain metastases ecosystems.

EMBO molecular medicine·2026
Same journal

Obeticholic acid alleviates lupus pathology by inhibiting T follicular helper cell differentiation.

EMBO molecular medicine·2026
Same journal

OTUB1 non-canonically inhibits TAB2 ubiquitination to govern microglia-mediated neuroinflammation.

EMBO molecular medicine·2026
See all related articles

Related Experiment Video

Updated: Apr 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Evolving targets for lipid-modifying therapy.

Rose Q Do1, Stephen J Nicholls2, Gregory G Schwartz3

  • 1VA Medical Center, University of Colorado School of Medicine, Denver, CO, USA.

EMBO Molecular Medicine
|August 31, 2014
PubMed
Summary
This summary is machine-generated.

This review explores methods to alter lipoprotein levels, crucial for understanding atherosclerosis. It focuses on clinical approaches targeting low-density lipoprotein, lipoprotein (a), and high-density lipoprotein for better cardiovascular health.

Keywords:
atherosclerosischolesterollipoproteinstriglycerides

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.3K

Related Experiment Videos

Last Updated: Apr 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.3K

Area of Science:

  • Cardiovascular Science
  • Lipid Metabolism
  • Atherosclerosis Pathogenesis

Background:

  • Atherosclerosis development is closely linked to lipoprotein concentration and function.
  • Various lipoprotein classes play distinct roles in disease progression.

Purpose of the Study:

  • To review current and novel strategies for modifying lipoprotein profiles.
  • To highlight therapeutic approaches that have reached clinical evaluation.

Main Methods:

  • Examination of existing and emerging lipoprotein modification techniques.
  • Focus on strategies targeting low-density lipoprotein (LDL), lipoprotein (a) [Lp(a)], triglyceride-rich lipoproteins (TRLs), and high-density lipoprotein (HDL).
  • Discussion of nuclear receptor and phospholipase targeting.

Main Results:

  • Several therapeutic strategies for modifying lipoproteins have advanced to clinical trials.
  • Targeting specific lipoprotein subclasses offers potential for atherosclerosis management.

Conclusions:

  • Lipoprotein modification represents a key therapeutic avenue for atherosclerosis.
  • Further clinical evaluation of these emerging strategies is warranted for cardiovascular disease prevention.